AE Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $684K | Sell |
1,094
-5,587
| -84% | -$3.8M | ﹤0.01% | 1074 |
|
|
2026
Q1 | $5.16M | Buy |
6,681
+1,207
| +22% | +$924K | 0.03% | 413 |
|
|
2025
Q4 | $4.23M | Buy |
5,474
+1,470
| +37% | +$998K | 0.02% | 434 |
|
|
2025
Q3 | $2.25M | Buy |
4,004
+1,371
| +52% | +$775K | 0.01% | 536 |
|
|
2025
Q2 | $1.38M | Buy |
2,633
+408
| +18% | +$228K | 0.01% | 634 |
|
|
2025
Q1 | $1.41M | Buy |
2,225
+445
| +25% | +$306K | 0.01% | 622 |
|
|
2024
Q4 | $1.27M | Buy |
1,780
+706
| +66% | +$592K | 0.01% | 650 |
|
|
2024
Q3 | $1.13M | Buy |
1,074
+527
| +96% | +$586K | 0.01% | 668 |
|
|
2024
Q2 | $575K | Buy |
547
+89
| +19% | +$86.3K | 0.01% | 850 |
|
|
2024
Q1 | $441K | Sell |
458
-3,210
| -88% | -$3.05M | 0.01% | 855 |
|
|
2023
Q4 | $3.45M | Buy |
3,668
+2,450
| +201% | +$2.02M | 0.02% | 718 |
|
|
2023
Q3 | $1M | Sell |
1,218
-2,031
| -63% | -$1.6M | 0.01% | 1093 |
|
|
2023
Q2 | $2.33M | Sell |
3,249
-631
| -16% | -$487K | 0.01% | 800 |
|
|
2023
Q1 | $3.19M | Sell |
3,880
-677
| -15% | -$511K | 0.02% | 640 |
|
|
2022
Q4 | $3.29M | Sell |
4,557
-8,384
| -65% | -$6.19M | 0.02% | 589 |
|
|
2022
Q3 | $8.91M | Buy |
12,941
+82
| +0.6% | +$51.6K | 0.07% | 302 |
|
|
2022
Q2 | $7.6M | Buy |
12,859
+2,845
| +28% | +$1.85M | 0.06% | 334 |
|
|
2022
Q1 | $6.99M | Buy |
10,014
+176
| +2% | +$111K | 0.05% | 362 |
|
|
2021
Q4 | $6.21M | Buy |
9,838
+5,658
| +135% | +$3.48M | 0.04% | 377 |
|
|
2021
Q3 | $2.53M | Sell |
4,180
-169
| -4% | -$105K | 0.02% | 573 |
|
|
2021
Q2 | $2.43M | Buy |
4,349
+601
| +16% | +$304K | 0.02% | 575 |
|
|
2021
Q1 | $1.77M | Buy |
3,748
+3,044
| +432% | +$1.48M | 0.02% | 603 |
|
|
2020
Q4 | $340K | Sell |
704
-1,436
| -67% | -$775K | ﹤0.01% | 1091 |
|
|
2020
Q3 | $1.2M | Buy |
2,140
+236
| +12% | +$143K | 0.02% | 583 |
|
|
2020
Q2 | $1.19M | Buy |
1,904
+514
| +37% | +$292K | 0.02% | 566 |
|
|
2020
Q1 | $679K | Buy |
1,390
+808
| +139% | +$333K | 0.02% | 589 |
|
|
2019
Q4 | $219K | Buy |
+582
| New | +$196K | ﹤0.01% | 1035 |
|
|
2019
Q3 | – | Sell |
-705
| Closed | -$221K | – | 1055 |
|
|
2019
Q2 | $221K | Buy |
+705
| New | +$235K | 0.01% | 865 |
|
|
2018
Q1 | – | Sell |
-548
| Closed | -$206K | – | 467 |
|
|
2017
Q4 | $206K | Buy |
+548
| New | +$222K | 0.02% | 393 |
|
Other funds holding REGN
AE Wealth Management's REGN Position: Q2 2026 in Review
AE Wealth Management reduced its Regeneron Pharmaceuticals (REGN) stake by 84% in Q2 2026, selling an estimated $3.8M and leaving 1,094 shares worth $684K. The position accounts for ﹤0.01% of the portfolio, ranked #1074.
AE Wealth Management first reported a position in REGN in Q4 2017 and has held it in 29 quarters since. The position peaked at $8.91M in Q3 2022. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- AE Wealth Management held 1,094 shares of Regeneron Pharmaceuticals worth $684K as of Q2 2026.
- AE Wealth Management sold 5,587 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $3.8M.
- Regeneron Pharmaceuticals made up ﹤0.01% of AE Wealth Management's portfolio in Q2 2026, its #1074 holding.
- AE Wealth Management first reported a position in Regeneron Pharmaceuticals in Q4 2017 and has held it in 29 quarters since.
- AE Wealth Management's Regeneron Pharmaceuticals position peaked at $8.91M in Q3 2022.
- 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on AE Wealth Management's 13F filing for Q2 2026, filed 3 Aug 2026.